

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/012066-2022>

Award

Procurement of Lutetium (177Lu) oxodotreotide (Luthathera) PRRT

BELFAST HEALTH AND SOCIAL CARE TRUST

F15: Voluntary ex ante transparency notice

Notice identifier: 2022/S 000-012066

Procurement identifier (OCID): ocids-h6vhtk-0335bf

Published 9 May 2022, 5:52pm

Section I: Contracting authority/entity

I.1) Name and addresses

BELFAST HEALTH AND SOCIAL CARE TRUST

LISBURN ROAD

BELFAST

BT97AB

Contact

Norma Moore

Email

norma.moore@belfasttrust.hscni.net

Country

United Kingdom

Region code

UKN06 - Belfast

Internet address(es)

Main address

<https://belfasttrust.hscni.net>

I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

Procurement of Lutetium (177Lu) oxodotreotide (Luthathera) PRRT

Reference number

DAC10464

II.1.2) Main CPV code

- 33000000 - Medical equipments, pharmaceuticals and personal care products

II.1.3) Type of contract

Supplies

II.1.4) Short description

Procurement of Lutetium (177Lu) oxodetreotide (Luthathera) PRRT

II.1.6) Information about lots

This contract is divided into lots: No

II.1.7) Total value of the procurement (excluding VAT)

Value excluding VAT: £1,000,000

II.2) Description

II.2.3) Place of performance

NUTS codes

- UKN - Northern Ireland

Main site or place of performance

Belfast Health and Social Care Trust

II.2.4) Description of the procurement

Procurement of Lutetium (^{177}Lu) oxodotreotide (Luthathera) PRRT

II.2.5) Award criteria

Price

II.2.11) Information about options

Options: No

Section IV. Procedure

IV.1) Description

IV.1.1) Type of procedure

Negotiated without a prior call for competition

- The works, supplies or services can be provided only by a particular economic operator for the following reason:
 - protection of exclusive rights, including intellectual property rights

Explanation:

No other reasonable alternative or substitute exists for this procurement and the absence of competition is not a result of the artificial narrowing of the parameters of the procurement. Lutetium (^{177}Lu) oxodotreotide (Lutathera) is a licensed radiopharmaceutical for the treatment of unresectable or metastatic, progressive, well-differentiated somatostatin receptor positive gastro-entero-pancreatic neuroendocrine (GEP) tumours in adults. The supplier, Advanced Accelerator Applications (AAA), holds the unique patent and licence for this product. This is the only licenced Peptide Receptor Radionuclide Therapy (PRRT) in Europe.

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

Section V. Award of contract/concession

Contract No

DAC10464

Title

Procurement of Lutetium (^{177}Lu) oxodetreotide (Lutathera) PRRT

A contract/lot is awarded: Yes

V.2) Award of contract/concession

V.2.1) Date of conclusion of the contract

9 May 2022

V.2.2) Information about tenders

The contract has been awarded to a group of economic operators: No

V.2.3) Name and address of the contractor/concessionaire

Advanced Accelerator Applications (UK & Ireland) Ltd

Edison House, 223-231 Old Marylebone Road

London

NW1 1QT

Country

United Kingdom

NUTS code

- UKI - London

Internet address

www.adacap.com

The contractor/concessionaire is an SME

No

V.2.4) Information on value of contract/lot/concession (excluding VAT)

Initial estimated total value of the contract/lot/concession: £1,000,000

Total value of the contract/lot/concession: £1,000,000

Section VI. Complementary information

VI.4) Procedures for review

VI.4.1) Review body

Belfast Health and Social Care Trust

Belfast

BT8 8BH

Email

norma.moore@belfasttrust.hscni.net

Country

United Kingdom

Internet address

<https://belfasttrust.hscni.net>